JeanClaude Maurel - Medesis Pharma Pres CEO
| ALMDP Stock | EUR 0.35 0.01 2.94% |
Insider
JeanClaude Maurel is Pres CEO of Medesis Pharma SA
| Phone | 33 4 67 03 03 96 |
| Web | https://www.medesispharma.com |
Similar Executives
| Showing other executives | INSIDER Age | ||
| Linda MSc | OSE Pharma SA | 56 | |
| Anne Pascard | Abivax SA | N/A | |
| FFPM MBA | Biophytis SA | 52 | |
| Philippe Rousseau | Biophytis SA | 52 | |
| Dominique MD | OSE Pharma SA | 68 | |
| Kader Hidra | Hydrogen Refueling Solutions | N/A | |
| JeanPascal PharmD | OSE Pharma SA | N/A | |
| Francis Eynard | Hydrogen Refueling Solutions | N/A | |
| Paul Gineste | Abivax SA | N/A | |
| Adamo Screnci | Hydrogen Refueling Solutions | N/A | |
| Regina Jehle | Abivax SA | N/A | |
| Brangre Vasseur | OSE Pharma SA | N/A | |
| Teylan | Biophytis SA | N/A | |
| Silvia MD | OSE Pharma SA | N/A | |
| Hassen Rachedi | Hydrogen Refueling Solutions | N/A | |
| Raquel Lizarraga | Abivax SA | N/A | |
| Olivier Dhez | Hydrogen Refueling Solutions | N/A | |
| Benoit Canolle | Biophytis SA | 45 | |
| Alain MD | OSE Pharma SA | N/A | |
| Prof Ehrlich | Abivax SA | N/A | |
| Philippe MD | Abivax SA | 65 | |
Medesis Pharma SA Management Team
Elected by the shareholders, the Medesis Pharma's board of directors comprises two types of representatives: Medesis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medesis. The board's role is to monitor Medesis Pharma's management team and ensure that shareholders' interests are well served. Medesis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medesis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Solene Guilliot, Member Devel | ||
| JeanClaude Maurel, Pres CEO | ||
| Tessa Olivato, Member Financial |
Medesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medesis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 8.67 M | |||
| Shares Outstanding | 4.39 M | |||
| Shares Owned By Insiders | 17.28 % | |||
| Price To Book | 74.91 X | |||
| Price To Sales | 189.31 X | |||
| Revenue | 95.73 K | |||
| EBITDA | (3.05 M) | |||
| Net Income | (2.65 M) | |||
| Cash And Equivalents | 2.89 M | |||
| Total Debt | 1.28 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Medesis Stock Analysis
When running Medesis Pharma's price analysis, check to measure Medesis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medesis Pharma is operating at the current time. Most of Medesis Pharma's value examination focuses on studying past and present price action to predict the probability of Medesis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medesis Pharma's price. Additionally, you may evaluate how the addition of Medesis Pharma to your portfolios can decrease your overall portfolio volatility.